Progyny (NASDAQ:PGNY) Price Target Raised to $26.00

Progyny (NASDAQ:PGNY) had its price target hoisted by JPMorgan Chase & Co. from $25.00 to $26.00 in a report published on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities analysts have also weighed in on PGNY. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective (up previously from $26.00) on shares of Progyny in a research report on Friday, August 8th. Truist Financial lifted their target price on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Progyny in a report on Wednesday, October 8th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Finally, Raymond James Financial set a $28.00 price objective on Progyny in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

Progyny Stock Up 1.5%

PGNY opened at $24.42 on Tuesday. The firm has a market cap of $2.11 billion, a P/E ratio of 38.76, a PEG ratio of 2.05 and a beta of 1.29. Progyny has a 52 week low of $13.39 and a 52 week high of $26.76. The business’s fifty day simple moving average is $20.95 and its 200 day simple moving average is $21.89.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, November 6th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.06. The firm had revenue of $313.35 million during the quarter, compared to the consensus estimate of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. As a group, equities analysts expect that Progyny will post 0.6 EPS for the current fiscal year.

Insider Buying and Selling at Progyny

In other Progyny news, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the transaction, the executive vice president owned 79,697 shares in the company, valued at $1,829,843.12. This trade represents a 2.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders have sold 5,395 shares of company stock valued at $124,211. 9.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. California State Teachers Retirement System grew its position in shares of Progyny by 0.7% during the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after buying an additional 457 shares during the last quarter. Leibman Financial Services Inc. boosted its stake in Progyny by 1.1% in the second quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock valued at $1,011,000 after acquiring an additional 513 shares during the period. Teza Capital Management LLC boosted its stake in Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after acquiring an additional 516 shares during the period. Aristides Capital LLC grew its holdings in shares of Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after purchasing an additional 528 shares during the last quarter. Finally, Oxford Asset Management LLP raised its position in shares of Progyny by 4.3% during the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after purchasing an additional 531 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.